These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38561819)

  • 1. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients.
    Yuan H; Li N; Wu L; Yao H
    J Ovarian Res; 2024 Apr; 17(1):70. PubMed ID: 38561819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
    Ma Y; Liu J; Li N; Bu H; Huang Y; Jin C; Wen H; Feng S; Zhang H; Yang X; Kong B; Wu L; Song K
    J Ovarian Res; 2023 Oct; 16(1):209. PubMed ID: 37891662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
    Park J; Kim SI; Jeong SY; Kim Y; Bookman MA; Kim JW; Kim BG; Lee JY
    Gynecol Oncol; 2022 Apr; 165(1):97-104. PubMed ID: 35153073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
    Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E
    Anticancer Res; 2022 Apr; 42(4):2017-2022. PubMed ID: 35347023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
    Levine MD; Wang H; Sriram B; Khan A; Senter L; McLaughlin EM; Bixel KL; Chambers LM; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Backes FJ
    Gynecol Oncol; 2024 Mar; 182():51-56. PubMed ID: 38262238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
    Ehmann S; Lam C; Zhou Q; Iasonos A; Grisham RN; Tew WP; O'Cearbhaill RE; Long Roche K; Zivanovic O; Sonoda Y; Chi DS; Gardner GJ
    Gynecol Oncol; 2024 Jul; 186():104-109. PubMed ID: 38640773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer.
    Guo Y; Chen X; Tang X; Pan S; Zhu T; Zhang Y
    Curr Cancer Drug Targets; 2024; 24(7):733-748. PubMed ID: 38173064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.
    Romeo M; Gil-Martín M; Gaba L; Teruel I; Taus Á; Fina C; Masvidal M; Murata P; Fernández-Plana J; Martínez A; Pérez C; García Y; Rodriguez V; Cros S; Parera M; Zanui M; Catot S; Pardo B; Plaja A; Esteve A; Barretina-Ginesta MP
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
    Ledermann JA; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Coleman RL
    Lancet Oncol; 2020 May; 21(5):710-722. PubMed ID: 32359490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
    Valenza C; Trapani D; Gandini S; Sposetti C; Boscolo Bielo L; Marra A; Giarratano T; Favero D; Cortesi L; Moscetti L; Pistelli M; Berardi R; Zambelli A; Lambertini M; Del Mastro L; Guarneri V; Vernieri C; Curigliano G
    Eur J Cancer; 2023 Sep; 190():112944. PubMed ID: 37437366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
    Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
    [No Abstract]   [Full Text] [Related]  

  • 13. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
    Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
    Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy.
    Zhang N; Zheng H; Gao Y; Shu T; Wang H; Cai Y
    J Ovarian Res; 2024 Mar; 17(1):55. PubMed ID: 38444005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Rodriguez-Freixinos V; Fariñas-Madrid L; Gil-Martin M; Barretina-Ginesta P; Romeo M; Villacampa G; Pardo B; Ahmed H; Recalde S; Piulats JM; Gómez-Plaza MC; Gil-Moreno A; Sala E; Martínez-Román S; Ponce J; Meléndez C; Carballas E; Dienstmann R; Oaknin A
    Gynecol Oncol; 2019 Feb; 152(2):270-277. PubMed ID: 30551885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.
    Sivakumaran T; Krasovitsky M; Freimund A; Lee YC; Webber K; So J; Norris C; Friedlander M; Mileshkin L; Au-Yeung G
    Int J Gynecol Cancer; 2022 Jul; 32(7):906-912. PubMed ID: 35321889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
    Ang JE; Gourley C; Powell CB; High H; Shapira-Frommer R; Castonguay V; De Greve J; Atkinson T; Yap TA; Sandhu S; Banerjee S; Chen LM; Friedlander ML; Kaufman B; Oza AM; Matulonis U; Barber LJ; Kozarewa I; Fenwick K; Assiotis I; Campbell J; Chen L; de Bono JS; Gore ME; Lord CJ; Ashworth A; Kaye SB
    Clin Cancer Res; 2013 Oct; 19(19):5485-93. PubMed ID: 23922302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy and safety of anlotinib combined with niraparib in treating patients with platinum-resistant recurrent ovarian cancer].
    Yang M; Wang JJ; Deng SQ; Liang SS; Sun L
    Zhonghua Zhong Liu Za Zhi; 2024 Jul; 46(7):696-702. PubMed ID: 39034805
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.
    Yang Y; Ai X; Xu H; Yang G; Yang L; Hao X; Yang K; Mi Y; Wang G; Zhang S; Lei S; Wang Y
    Thorac Cancer; 2022 Dec; 13(23):3295-3303. PubMed ID: 36218023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    Frenel JS; Kim JW; Aryal N; Asher R; Berton D; Vidal L; Pautier P; Ledermann JA; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Colombo N; Park-Simon TW; Tamura K; Sonke GS; Freimund AE; Lee CK; Pujade-Lauraine E
    Ann Oncol; 2022 Oct; 33(10):1021-1028. PubMed ID: 35772665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.